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Introduction 
Although poor response to neuroleptics has traditionally been 
considered a characteristic feature of negative schizophrenic 
symptoms (Crow 1980; Andreasen et aJ 1982), several recent 
studies have documented significant improvement in negative 
symptoms in schizophrenic patients treated with neuroleptics (Breier 
et al 1987; vanKammen et al 1987; Kay and Singh 1989; Tendon 
et al 1990; Meltzer, 1990, Serban et al 1992). The question of 
whether neuroleptic-induced improvement in negative symptoms 
is linked to concomitant improvement in positive symptoms 
(vanKammen et al 1987; Tendon et al 1990; Meltzer 1990) or 
occurs independently of such improvement (Breier et al 1987; 
Serban et al 1992) is unresolved. This issue has obvious patho- 
physiological and therapeutic relevance. 
in a previous study (Tendon et al 1990), we had observed a 
significant improvement in negative symptoms with four weeks 
of neuroleptic treatment in a sample of forty schizophrenic in- 
patients; a significant correlation between change in positive and 
negative symptoms was also noted, in an effort to replicate these 
findings and further evaluate to covariance of positive and neg, 
ative symptoms in the course of initial neuroleptic treatment, we 
assessed positive ~nd negative symptoms in another nonoveflap- 
ping sample of 80 schizophrenic inpatients at drug-free baseline 
and four weeks after clinically determined neuroleptic treatment. 
Materials and Methods 
The sample consisted of 80 consecutively hospitalized patients 
admitted to the University of Michigan Schizophrenia Program. 
Diagnostic evaluation included a structured interview using the 
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Schedule of Affective Disorders and Schizophrenia (SADS) (En- 
dicott and Spitzer 1978) as well as all available history and 
clinical observations. Patients had to meet both Research Di- 
agnostic Criteria (RDC) (Spitzer et el. 1978) and DSM-III-R 
criteria (American Psychiatric Association 198"1) for schizo- 
phrenia and give informed consent for participation in the study, 
The sample consisted of 50 men and 30 women with a mean - 
SD age of 29 -+ 8 years and a mean duration of illness of 
8 _+ 6 years, Twenty of the patients had never previously received 
any psychotropic medication. 
Baseline clinical ratings were performed after patients were 
medication free for at least two weeks. Patients were then placed 
on clinically determined doses of haloperidol or thiothixcne sin- 
gly, or in combination with an anticholinergic agent if they de- 
veloped extrapyramidal side-effects. After about four weeks of 
neuroleptic treatment, clinical ratings were repeated. Patients 
were rated on the Brief Psychiatric Rating Scale (BPRS) (Overall 
and Gorham 1962), and the Scale for the Assessment of Negative 
Symptoms (SANS) (Andreasen 1983) at both timepoints. As- 
sessment of global severity was made by the 18-item BPRS total 
score. Positive symptoms were assessed by the sum of the fol- 
lowing four BPRS items: conceptual disorganization, suspicious- 
ness, hallucinatory behavior, and unusual thought content. Neg- 
ative symptoms were assessed by the SANS, with the sum of 
global scores being used for analysis. 
Paired two-tailed Students t-tests were performed to compare 
the symptom ratings at baseline to those in the post-treatment 
phase. Correlation analysis between change in posiiive symptoms 
and ch~ngc in negative symptoms was conducted to evaluate the 
covariance of these symptom clusters. 
Results 
Both positive and negative symptoms improved significantly (p 
< 0.001) with neuroleptic treatment (Table I). Positive symp- 
toms improved to a greater extent than negative symptoms. Drug- 
naive and previously-treated patients showed the same pattern 
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Table !. Positive and Negative Symptoms at Baseline and Following Four Weeks of Neuroleptic Treatment 
Significance 





Global severity (BPRS Total) 50.2 - 8.6 36.6 ± 7.9 18.1 <0.0001 27 
Positive symptoms (BPRS 15.6.4- 2.9 10.1 ± 3.2 17.2 <0.0001 35 
'n'HOT') 
Negative symptoms (BPRS 11.3 ± 2.9 8.4 ± 2.2 14.0 <0.0001 26 
"ANER") 
Negative symptoms (SANS 12.5 - 4.2 8.6 +- 3,4 13.3 <0.(3001 30 
sum of global scores) 
Individual SANS scales 
Affective flattening 2,6 - 0.97 1,9 - 0.83 9.5 <0.001 27 
Alogia 2,1 - 1,04 1,4 -. 0,80 9.0 <0.001 32 
Avolition-apathy 2.6 --. 1,01 1,7 • 0,76 10.3 <0,001 33 
Anhedonia-asociality 3,1 ± 0,82 2,3 - 0.74 10.7 <0.001 26 
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Figure I, Relationship between change in positive and negative 
symptoms with neuroleptic treatment (N = 80). 
of improvement, Use of the BPRS "ANER" factor (emo~i~,nal 
withdrawal, motor retardation, and blunted affect) instead of the 
SANS sum of global scores to define negative symptoms did not 
alter the findings. There was a significant reduction in global 
scores on all five subscales of the SANS. 
Change in positive symptoms was significantly correlated to 
change in negative symptoms (r -- 0.60, 
p < 0.001) (Figure I). Change in positive symptoms was also 
significantly correlated to change in each of the individual SANS 
global scales (affective flattening: r -- 0.37, p < .01; alogia: r 
= 0.49, p < 0.01; avolition-apathy: r = 0.4.8, p < 0.01, 
anhedonia-asociality: r -- 0.39, p < 0.01; attention: r -- 0.56; 
p < 0.01). 
Discussion 
In agreement with the findings of other recent studies (Breier et 
al 1987; vanKammen et al 1987; Kay and Singh 1989; Tandon 
et al 1990; Meltzer, 1990; Serban et ai 1992), these data confirm 
that both positive and negative symptoms improve significantly 
with neuroleptic treatment, Similar to the findings of these stud- 
ies, we observed that positive symptoms improved to a greater 
extent than negative symptoms, The significant correlation be- 
tween change in positive and negative symptoms noted in this 
study is in agreement with our previous study and the findings 
of vanKammen et al (I 987) and Meltzer (1990), but inconsistent 
with Breier et al (1987) and Serban et ai, (1992), who did not 
find such a relationship, I~reicr et al 's inability to find this re- 
lationship may have been related to their relatively small sample 
size (19), Serban et al (1992) studied a sample of "negative 
schizophrenics" and excluded patients with more than moderate 
positive symptoms; their ability to detect covariance between 
positive and negative symptoms may have been limited by the 
restricted range of positive symptoms in their sample, Meltzer 
(1990) noted covariance of positive and negative symptoms in 
the course of treatment of schizophrenic patients with typical 
neureleptics but not with clozapine, 
The covariance of positive and negative symptoms in the 
course of initial neuroleptic treatment indicates that common or 
related pathophysiological mechanisms may underlie positive and 
negative symptoms in the psychotic phase of the illness. These 
data are consistent with the notion that only secondary negative 
symptoms (secondary to positive symptoms; Carpenter et al 1985) 
are responsive to treatment with typical neuroleptics. Alterna- 
tively, the concurrent improvement in positive and negative 
symptoms observed in our study can also be explained by the 
recently proposed model of dopaminergic/cholinergic interac- 
tions in schizophrenia (Tandon and Greden 1989), which sug- 
gests that distinct but related pathophysiological mechanisms 
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underlie positive (dopaminergic hyperactivity) and negative (cho- 
linergic hyperactivity) symptoms in the psychotic phase of the 
illness. 
These data are inconsistent with the characterization of neg- 
ative symptoms as always being neuroleptic nonresponsive and 
suggest that common or related mechanisms may underlie pos- 
itive and negative symptoms in the psychotic phase of the illness. 
The question of whether clozapine differs from typical neuro- 
leptics with regard to the covariance of positive and negative 
symptoms during treatment requires further study. 
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